Cite
HARVARD Citation
Giannatempo, P. et al. (n.d.). 18TiPDESIGN OF A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN (SGN-35) AS SALVAGE THERAPY FOR MALES WITH CHEMORESISTANT GERM-CELL TUMORS (GCT). Annals of oncology. p. vi6. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Giannatempo, P. et al. (n.d.). 18TiPDESIGN OF A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN (SGN-35) AS SALVAGE THERAPY FOR MALES WITH CHEMORESISTANT GERM-CELL TUMORS (GCT). Annals of oncology. p. vi6. [Online].